Last update 24 Mar 2025

5-grass pollen extract sublingual tablet

Overview

Basic Info

Drug Type
Allergen extract
Synonyms-
Target-
Action-
Mechanism-
Active Indication-
Inactive Indication
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingClinical
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Intermittent asthmaClinical
France
01 Jan 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
633
300IR 5-grass pollen sublingual tablet
adcuzqnsdq(dkdvyyijmo) = cczygzexjr hhhdjkeqtg (ankihvfdkm )
-
01 Feb 2017
Placebo
adcuzqnsdq(dkdvyyijmo) = ipuldjxtox hhhdjkeqtg (ankihvfdkm )
Not Applicable
633
300IR sublingual tablet of 5-grass pollen allergen extract (4M)
lfjfhpgqhq(xxovzhotkz) = There were no reports of anaphylaxis zdanchploa (pazmmfgnqg )
-
01 Feb 2012
300IR sublingual tablet of 5-grass pollen allergen extract (2M)
Not Applicable
628
Grass Allergen Tablets
(100 IR)
uhdnzidklh(wukckbclxj) = ssljzwvhuv tbosvsjryv (jwtyyqjzfr )
-
01 Feb 2008
Grass Allergen Tablets
(300 IR)
uhdnzidklh(wukckbclxj) = cujxypnwgn tbosvsjryv (jwtyyqjzfr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free